, Tracking Stock Market Picks
Enter Symbol:

up 248.91 %

PHARMASSET INC. (VRUS) rated Buy with price target $104 by ThinkEquity

Posted on: Friday,  Apr 1, 2011  8:25 AM ET by ThinkEquity

ThinkEquity rated Buy PHARMASSET INC. (NASDAQ: VRUS) on 04/01/2011, when the stock price was $39.25. Since
then, PHARMASSET INC. has gained 248.92% as of 01/17/2012's recent price of $136.95.
If you would have followed this ThinkEquity's recommendation on VRUS, you would have gained 248.91% of your investment in 291 days.

Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of drugs to treat viral infections. It focuses on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/1/2011 8:25 AM Buy
39.25 52.00
as of 12/30/2011
1 Week up  4.21 %
1 Month down  -2.12 %
3 Months up  55.63 %
1 YTD up  231.50 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/8/2011 8:25 AM Buy
33.13 37.50
1/7/2011 8:25 AM Hold
22.85 22.50
9/8/2009 8:25 AM Buy
10.15 14.50
1/27/2009 8:25 AM Buy
5.41 10.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy